CD1d is a non-polymorphic glycoprotein expressed on the surface of antigen-presenting cells (APCs). It is specifically associated with presenting lipid antigens that activate the distinctive class of T cells known as invariant Natural Killer T (*i*NKT) cells. *i*NKT cells display characteristics of both T cells and NK cells and play a crucial role in diverse immune responses and other pathologic conditions.[@bib1; @bib2; @bib3; @bib4] When the synthetic glycolipid α-galactosyl ceramide (α-GalCer),[@bib5] also known as KRN7000 (**1**, [Fig. 1](#fig1){ref-type="fig"}), is bound to CD1d and presented to T cell receptors (TCRs) on the surface of *i*NKT cells, the latter are activated to release diverse cytokines, including both Th1 and Th2 cytokines.[@bib6; @bib7; @bib8] Similar results are obtained with the more readily obtained C24:0 analogue (**2**, [Fig. 1](#fig1){ref-type="fig"}).[@bib9; @bib10] It is believed that the release of Th1 cytokines may contribute to antitumour and antimicrobial functions, whilst the secretion of Th2 cytokines may help alleviate autoimmune diseases[@bib11; @bib12; @bib13] such as multiple sclerosis[@bib14] and arthritis.[@bib15] The opposing effects induced by Th1 and Th2 cytokines have complicated efforts to develop KRN7000 as a therapeutic agent, since it induces high levels of both types of cytokine and therefore may induce mixed and unpredictable biological effects.[@bib16] Switching the C26:0 acyl chain of KRN7000 for a C20 11,14-*cis*-diene acyl chain modifies the outcome of *i*NKT cell activation and potently induces a Th2-biased cytokine response.[@bib9] This C20:2 analogue (**3**, [Fig. 1](#fig1){ref-type="fig"}) also exhibits less stringent requirements for loading on to CD1d.[@bib10]

Although extensive studies have examined the impact on the *i*NKT cell-stimulating activities of modifications to the fatty acyl and sphingosine structures of α-GalCer, there has been less analysis of the effects of structural modifications of the carbohydrate head group.[@bib17] Subtle changes in this part of the glycolipid are likely to have significant effects on *i*NKT cell recognition since the monosaccharide group is exposed and makes direct contacts with the TCR in complexes formed by the binding of α-GalCer to CD1d.[@bib18] To this end, we now report the synthesis and preliminary biological activity of α-glucosyl ceramide analogues **4** and **5** ([Fig. 2](#fig2){ref-type="fig"}).

Since targets **4** and **5** differ only in their acyl chain substitution, we elected to pursue a synthetic strategy that would allow the introduction of this point of diversity in the final step. We therefore examined several routes to amine **11** from which both glucosyl ceramide targets would then be accessed through chemoselective acylation of the amino residue. The key challenge in a synthesis of amine **11** is to form the glycosidic linkage with high α-selectivity. To this end, we first opted to employ a stereospecific glucosylation method developed by Bols ([Scheme 1](#fig4){ref-type="fig"}).[@bib19] This method involves the use of a silyl tether to attach the acceptor temporarily to the 2-position of the glucosyl donor prior to the key glycosylation step. Glycosylation proceeds with 1,2-*syn* specificity, owing to the formation of a five-membered silylacetal intermediate, which in the case of glucosyl donors, ensures the formation of the α-glycoside product. Thioglucoside **7**, synthesised in three steps from [d]{.smallcaps}-glucal **6**,[@bib20] was reacted with a fivefold excess of dichlorodimethylsilane. This reaction afforded a silyl chloride intermediate, which, after removal of the excess dichlorosilane reagent under reduced pressure, reacted with known alcohol **8**[@bib21] to form mixed silyl acetal **9**, our glucosylation precursor, in modest yield. Treatment of silyl acetal **9** with *N*-iodosuccinimide (NIS) furnished the desired glucoside **10** as a single diastereoisomer, albeit in modest yield. Hydrogenolysis of the benzyl groups and reduction of the azide in **10** using Pd(OH)~2~ as the catalyst,[@bib22] provided our acylation precursor, amine **11** in 57% yield ([Scheme 1](#fig4){ref-type="fig"}).

Although this synthetic approach allowed a completely stereoselective route to our target amine **11**, a number of steps in the sequence suffered from poor yields, which hindered access to significant quantities of material. We therefore examined other glycosylation methods. Kobayashi has described a stereoselective α-glycosylation using a galactosyl bromide generated in situ from 2,3,4,6-tetra-*O*-benzyl galactose.[@bib23] Unfortunately, we found that glycosylation using the corresponding glucosyl bromide derived from **12** afforded significant amounts of the unwanted β-anomer ([Scheme 2](#fig5){ref-type="fig"}). The use of perbenzylated glucosyl fluoride **13**[@bib24] also provided a mixture of α- and β-glycosides **14**, which proved difficult to separate ([Scheme 2](#fig5){ref-type="fig"}).

We therefore turned our attention to the use of glucosyl iodides,[@bib25] specifically per-TMS-protected glucosyl iodide **16**, as an alternative donor. Du et al. have shown that the corresponding galactosyl iodide provides excellent levels of α-selectivity with a variety of alcohol acceptors.[@bib26] The reaction conditions for this glycosylation are also extremely mild and the silyl protecting groups are easily removed using an acid work-up. We reasoned that the use of phytosphingosine acceptor **17**,[@bib27] in which the internal 1,2-diol is protected as an acetal, would deliver the completely O-deprotected glucoside **18** upon acid work-up. To this end, 1,2,3,4,6-penta-*O*-trimethylsilyl glucose **15**, which is commercially available or can be readily synthesised on large scale by treating glucose with a mixture of TMSCl and hexamethyldisilazane (HMDS) in pyridine,[@bib28] was converted to glycosyl iodide **16** by treatment with TMSI in CH~2~Cl~2~ ([Scheme 3](#fig6){ref-type="fig"}). Adding a solution of crude **16** to a solution of alcohol **17**, *^n^*Bu~4~NI, Hünig's base and 4 Å molecular sieves in CH~2~Cl~2~ successfully effected glycosylation. Treating the initially formed glycoside product with *p*-toluenesulfonic acid (*p*TSA) in methanol provided the fully O-deprotected glycoside **18** as a single anomer. Although the yield for this three-step process was a modest 45%, we now had very rapid access to our target molecules. A final Staudinger reduction of azide **18** delivered our requisite amine **11** in quantitative yield ([Scheme 3](#fig6){ref-type="fig"}).[@bib29] This reaction sequence is short and scalable and proved to be particularly effective for accessing multigram quantities of amine **11**. The final acylation reactions were accomplished by adding either tetracosanoyl chloride or 11,14-eicosadienoyl chloride (formed from the corresponding carboxylic acids using oxalyl chloride) in THF to amine **11** in a vigorously stirred biphasic mixture of THF and 8 M NaOAc solution. Both reactions provided the desired amide products **4** and **5** in good yields ([Scheme 3](#fig6){ref-type="fig"}).[@bib30; @bib31]

To assess the biological activity of the α-glucosyl ceramides **4** and **5** and compare these to KRN7000 **1** and the α-galactosyl ceramide analogues **2** (C24:0) and **3** (C20:2), we assessed the ability of each compound to induce the expansion of *i*NKT cells in samples of human peripheral blood mononuclear cells (PBMC) during an eight-day in vitro culture.[@bib32] The results showed that both the percentages and absolute numbers of *i*NKT cells in the cultures were markedly increased to similar levels by stimulation with both of the α-GlcCer analogues **4** and **5** ([Fig. 3](#fig3){ref-type="fig"}). The level of *i*NKT cell expansion, at least with a relatively high concentration of the glycolipids (250 nM), was comparable for both of the *N*-acyl variants of α-GlcCer and very similar to levels obtained with the related α-GalCer analogues (**2** (C24:0) and **3** (C20:2)) and with the prototypical *i*NKT cell activator KRN7000 (**1** (C26:0)). Representative profiles obtained by flow cytometry of cultures from one normal blood donor are shown in [Figure 3](#fig3){ref-type="fig"}A. This analysis was carried out with PBMC from four separate donors ([Fig. 3](#fig3){ref-type="fig"}B). Although differences were observed for the levels of *i*NKT cell expansion between different donors, all donors responded well to the two α-GlcCer analogues. In all cases, these responses were similar to those generated by the analogous α-GalCer compounds.

The strong biological activity of the α-GlcCer compounds was consistent with findings from the initial study that described the reactivity of CD1d-restricted *i*NKT cells to synthetic glycosylceramides.[@bib5] This showed an α-GlcCer with a C26 saturated acyl group to be stimulatory for mouse *i*NKT cells, with a level of activity only slightly less than that of KRN7000 (**1**). Our analysis confirms the activity of α-GlcCer compounds as ligands for human *i*NKT cells. It is also notable that we observed human *i*NKT cell activation and expansion for an α-GlcCer with a shorter acyl chain containing unsaturations (**5**). Previous work with analogues of α-GalCer containing C20:2 or other unsaturated fatty acyl groups revealed a marked tendency for these to bias *i*NKT cell-dependent cytokine responses in mice to give preferential secretion of Th2 cytokines such as IL-4 and IL-13.[@bib9] This Th2 cytokine bias has been associated with therapeutic benefits in a variety of mouse models of autoimmune and inflammatory diseases, indicating potential therapeutic applications for such glycolipids in human diseases.[@bib17] It will thus be important to determine whether compound **5** or other α-GlcCer analogues bearing an unsaturated acyl chain also show an ability to induce Th2-biased cytokine responses, which is a focus for future studies.

In summary, we have developed an efficient route to α-glucosyl ceramides that provided two biologically active ligands **4** and **5** for stimulation of human *i*NKT cell responses. Of the range of glycosylation methods that were investigated for accessing the target molecules with high levels of stereoselectivity, the use of per-TMS-protected glucosyl iodide **16** as the donor is the most attractive, reacting with acceptor **17** to provide a single α-glycoside product. This glycosylation reaction is also scalable and with an acidic work-up effecting global deprotection, followed by Staudinger reduction of the azide, allows rapid access to advanced intermediate **11**, which can now be used to provide a broad range of α-GlcCer compounds with different acyl chains. Compounds produced using this approach will assist in expanding the current understanding of the structure--activity relationships for glycolipid activators of *i*NKT cells, which is of central importance to the further development of this class of compounds as clinically useful immunomodulators.
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![α-Galactosyl ceramides **1** (C26:0), **2** (C24:0) and **3** (C20:2).](gr1){#fig1}

![Target α-glucosyl ceramides **4** (C24) and **5** (C20:2).](gr2){#fig2}

![Ex vivo expansion of human *i*NKT cells by α-GlcCer and α-GalCer analogues. Peripheral blood mononuclear cells (PBMC) from four different donors were stimulated with the indicated glycolipids at a concentration of 250 nM in the presence of low levels of exogenous IL-2 and IL-7. At day 8, cultures were harvested and analysed by flow cytometry using monoclonal antibodies specific for CD3 and for the invariant TCRα chain expressed by *i*NKT cells (6B11). (A) Dot plots showing relative levels of CD3^+^ 6B11^+^*i*NKT cells are shown for one representative donor. Numbers in upper right quadrant indicate percentages of total lymphocytes that are *i*NKT cells. (B) Absolute numbers of *i*NKT cells in the cultures were determined by flow cytometry using fluorescent counting beads, and the values of *i*NKT cell fold expansion were determined by dividing by the input number of *i*NKT cells.](gr3){#fig3}

![Reagents: (a) Me~2~SiCl~2~, pyridine, toluene; (b) acceptor **8**, pyridine, toluene, 38% over two steps; (c) NIS, MeNO~2~, 47%; (d) H~2~, Pd(OH)~2~, CHCl~3~/MeOH (1:1), 57%.](gr4){#fig4}

![Reagents: (a) From **12**: CBr~4~, PPh~3~, CH~2~Cl~2~, then **8**, *^n^*Bu~4~NBr, tetramethyl urea, 67% (α:β ratio: 1:1); (b) from **13**: **8**, SnCl~4~, AgIO~4~, THF, 41% (α:β ratio: 5:1).](gr5){#fig5}

![Reagents: (a) TMSI, CH~2~Cl~2~; (b) **17**, *^n^*Bu~4~NI, *^i^*Pr~2~NEt, 4 Å molecular sieves, CH~2~Cl~2~; then *p*TSA, MeOH, 45% from **15**; (c) PMe~3~, wet THF, quant.; (d) tetracosanoyl chloride, THF/8 M NaOAc, 68%; (e) 11,14-eicosadienoyl chloride, THF/8 M NaOAc, 66%.](gr6){#fig6}
